Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-registry. Krüger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Müller T, Klinker H, Pathil A, Heyne R…

Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Kim NJ, Magee C, Cummings C, Park H, Khalili M. Hepatol Commun. 2018 Sep 24;2(10):1274-1283. doi: 10.1002/hep4.1246.  https://www.ncbi.nlm.nih.gov/pmc/a…

The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection. Falade-Nwulia O, Sulkowski M. J Hepatol. 2017 Feb;66(2):267-269. doi: 10.1016/j.jhep.2016.10.027.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC…

HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. Valencia La Rosa J, Ryan P, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, et al. (2018) …

Eine dankbare Aufgabe für die Hausärztin und den Hausarzt: Hepatitis C – Eine Erfolgsgeschichte  Philip Bruggmann  Prim Hosp Care Allg Inn Med. 2018;18(16): Veröffentlichung: 29.08.2018, doi.org/10.4414/phc-d.20…

Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents. Yousif MM, Elsadek Fakhr A, Morad EA, Kelani H, Hamed EF, Elsadek HM, Zahran MH, Fahmy Afify A, Ismail WA, Ela…